Literature DB >> 15301025

Safety-engineered device implementation: does it introduce bias in percutaneous injury reporting?

SeJean Sohn1, Janet Eagan, Kent A Sepkowitz.   

Abstract

OBJECTIVE: To examine whether implementation of safety-engineered devices in 2001 had an effect on rates of percutaneous injury (PI) reported by HCWs.
DESIGN: Before-and-after intervention trial comparing 3-year preintervention (1998--2001) and 2-year postintervention (2001--2002) periods. PI data from anonymous, self-administered surveys were prospectively entered into CDC NaSH software.
SETTING: A 427-bed, tertiary-care hospital in Manhattan. PARTICIPANTS: HCWs who attended state-mandated training sessions and completed the survey (1,132 preintervention; 821 postintervention). INTERVENTION: Implementation of a "safer-needle system" composed of various safety-engineered devices for needle-safe IV delivery-insertion, blood collection, and intramuscular-subcutaneous injection.
RESULTS: Preintervention, the overall annual rate of PIs self-reported on the survey was 36.5 per 100 respondents, compared with 13.9 per 100 respondents postintervention (P < .01). The annual rate of formally reported PIs decreased from 8.3 to 3.1 per 100 respondents (P < .01). Report rates varied by occupational group (P < or = .02). The overall rate did not change between study periods (22.7% to 22.3%), although reporting improved among nurses (23.6% to 44.4%, P = .03) and worsened among building services staff (90.5% to 50%, P = .03). HCWs with greater numbers of PIs self-reported on the survey were less likely to formally report injuries (P < .01). The two most common reasons for nonreport (ie, thought injury was low risk or believed patient was low risk for blood-borne disease) did not vary from preintervention to postintervention.
CONCLUSIONS: Safety-engineered device implementation decreased rates of PIs formally reported and self-reported on the survey. However, this intervention, with concomitant intensive education, had varying effects on reporting behavior by occupation and a minimal effect on overall reporting rates.

Entities:  

Mesh:

Year:  2004        PMID: 15301025     DOI: 10.1086/502437

Source DB:  PubMed          Journal:  Infect Control Hosp Epidemiol        ISSN: 0899-823X            Impact factor:   3.254


  6 in total

1.  Accessing Medical Care After a Needlestick Injury: First Responders' Perception of HIV Risk and Attitudes Toward Syringe Service Programs.

Authors:  Gregory Carter; Carrie Lawrence; Brennan Woodward; Anita Ohmit
Journal:  J Community Health       Date:  2020-06

2.  epic3: national evidence-based guidelines for preventing healthcare-associated infections in NHS hospitals in England.

Authors:  H P Loveday; J A Wilson; R J Pratt; M Golsorkhi; A Tingle; A Bak; J Browne; J Prieto; M Wilcox
Journal:  J Hosp Infect       Date:  2014-01       Impact factor: 3.926

3.  Pneumocystis S-adenosylmethionine transport: a potential drug target.

Authors:  Oscar Perez-Leal; Camilo Moncada; Allen B Clarkson; Salim Merali
Journal:  Am J Respir Cell Mol Biol       Date:  2011-06-03       Impact factor: 6.914

4.  Estimated risk of HIV acquisition and practice for preventing occupational exposure: a study of healthcare workers at Tumbi and Dodoma Hospitals, Tanzania.

Authors:  Kijakazi O Mashoto; Godfrey M Mubyazi; Emmanuel Makundi; Hussein Mohamed; Hamisi M Malebo
Journal:  BMC Health Serv Res       Date:  2013-09-30       Impact factor: 2.655

5.  Awareness of the Risk of Exposure to Infectious Material and the Behaviors of Polish Paramedics with Respect to the Hazards from Blood-Borne Pathogens-A Nationwide Study.

Authors:  Anna Garus-Pakowska; Mariusz Górajski; Franciszek Szatko
Journal:  Int J Environ Res Public Health       Date:  2017-07-27       Impact factor: 3.390

6.  Knowledge and Attitudes of Dentists with Respect to the Risks of Blood-Borne Pathogens-A Cross-Sectional Study in Poland.

Authors:  Anna Garus-Pakowska; Mariusz Górajski; Franciszek Szatko
Journal:  Int J Environ Res Public Health       Date:  2017-01-12       Impact factor: 3.390

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.